Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
Harvard Business School
Mallinckrodt
Dow
Colorcon

Last Updated: October 22, 2019

DrugPatentWatch Database Preview

Claims for Patent: 8,703,956

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,703,956
Title:Amorphous (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid
Abstract: The invention relates to a stable amorphous form of (5-Fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid and its use in the treatment of conditions mediated by the action of PGD.sub.2 at the CRTH2 receptor.
Inventor(s): Betancourt; Aimesther (Laval, CA), Lemieux; Marc (Laval, CA), Thibert; Roch (Laval, CA)
Assignee: Atopix Therapeutics Limited (Abingdon, Oxon, GB)
Application Number:13/414,328
Patent Claims:1. A stable composition comprising amorphous (5-Fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid (Compound 1) or a pharmaceutically or veterinarily acceptable salt thereof and a polymer selected from the group consisting of polyvinylpyrrolidone (PVP), polyvinylpyrrolidone-vinylacetate copolymer (PVP-VA), hydroxypropylmethylcellulose (HPMC), hypromellose-acetate-succinate (HPMCAS), and mixtures thereof.

2. The stable composition as claimed in claim 1, wherein the weight ratio of polymer to Compound 1 or salt thereof is from 1.5:1 to 15:1.

3. The stable composition as claimed in claim 1, wherein the weight ratio of polymer to Compound 1 or salt thereof is from 1.5:1 to 9:1.

4. The stable composition as claimed in claim 1, wherein the polymer is PVP, HMPC, PVP-VA, or mixtures thereof.

5. The stable composition as claimed in claim 4, wherein the polymer is PVP-VA.

6. The stable composition as claimed in claim 5, wherein the PVP-VA is a copolymer of 1-vinyl-2-pyrrolidone and vinyl acetate in a ratio of 6:4 by mass.

7. The stable composition as claimed in claim 4, wherein the polymer is PVP.

8. The stable composition as claimed in claim 7, wherein the PVP is PVP K30.

9. The stable composition as claimed in claim 1, which is a solid dispersion of Compound 1 or salt thereof in the polymer.

10. A process for preparing a stable composition as claimed in claim 9, the process comprising: ia. dissolving the polymer in a first solvent at a concentration of from 50-110 g/L; iia. adding solid crystalline Compound 1 or a pharmaceutically or veterinarily acceptable salt thereof to the solution to form a suspension, wherein the weight ratio of polymer to Compound 1 is from about 1.5:1 to 15:1; iiia. adding a second solvent, wherein the second solvent is chosen such that it is suitable to solubilise Compound 1 or the salt thereof and wherein the volume ratio of second solvent to first solvent is from 0.1:1 to 0.5:1; iva. stirring the mixture at about 5 to 60.degree. C. until a solution is obtained; va. removing solvent until the volume of solvent remaining is from about 20-50% of the total volume of solvent originally added; and either via. evaporating the solution to dryness; or viia adding a third solvent, wherein the third solvent is chosen such that it is suitable to solubilise Compound 1 or the salt thereof and wherein the amount of the third solvent is such that the total solids concentration in the solution (i.e. concentration of polymer+Compound 1) is from 5 to 15%; and viiia. spray drying the solution obtained in (viia) to obtain a solid dispersion of Compound 1 or the salt thereof in polymer.

11. The process as claimed in claim 10 wherein, in (ia), the first solvent is selected from the group consisting of methanol, dichloromethane, and a mixture thereof.

12. The process as claimed in claim 11, wherein the solvent is a 1:1 mixture (by volume) of methanol and dichloromethane.

13. The process as claimed in claim 10 wherein, in (iia), the amount of Compound 1 or salt thereof is chosen such that the weight ratio of polymer to Compound 1 or salt thereof is from about 1.5:1 to 9:1.

14. The process as claimed in claim 10 wherein, in (iiia), the second solvent is DMSO.

15. The process as claimed in claim 14 wherein the volume ratio of second solvent to first solvent is about 0.3:1.

16. The process as claimed in claim 10 wherein, in (va), the solvent is removed until the volume of solvent remaining is from about 20-50% of the total volume of solvent added (i.e. the total volume of the first and second solvents).

17. A process for preparing a stable composition as claimed in claim 9, the process comprising: ib. preparing a solution of Compound 1 and a polymer in a suitable solvent, wherein: the weight ratio of polymer to Compound 1 or salt thereof is at least 1.5:1, and the ratio of Compound 1:solvent is from about 1:35 to 1:65 w/v; and iib. spray drying the solution obtained in (ib) to obtain a solid dispersion.

18. The process as claimed in claim 17, wherein the solvent used in step (ib) is a mixture of DMSO and acetone, with the ratio of DMSO to acetone being from about 25:75 to 45:55 v/v.

19. The process as claimed in claim 18, wherein the ratio of DMSO to acetone is about 35:65 v/v.

20. A method for the treatment of a disease or condition selected from the group consisting of asthma, asthma exacerbations, chronic obstructive pulmonary disease, allergic rhinitis conjunctivitis, nasal polyps, atopic dermatitis, contact hypersensitivity (including contact dermatitis), eosiniphilic cough, eosinophilic bronchitis, eosinophilic gastroenteritis, eosinophilic oesophagitis, food allergies, inflammatory bowel disease, ulcerative colitis, Crohn's disease, mastocytosis, urticaria, hypereosinophilic syndrome, hyper IgE syndrome, infection, fibrotic diseases, Churg-Strauss syndrome, and multiple sclerosis, comprising administering to a patient in need of such treatment an effective amount of the stable composition as claimed in claim 1.

21. A kit for the treatment of a disease or condition mediated by the action of PGD.sub.2 at the CRTH2 receptor comprising a first container comprising the composition of claim 1 and a second container comprising one or more additional active agents.

22. The process of claim 17, wherein the weight ratio of polymer to Compound 1 or salt thereof in (ib) is from about 1.5:1 to about 15:1.

23. The composition of claim 1, further comprising a pharmaceutically acceptable excipient or carrier.

24. The composition as claimed in claim 1, further comprising one or more additional active agents selected from: Suplatast tosylate and similar compounds; .beta.2 adrenoreceptor agonists such as metaproterenol, isoproterenol, isoprenaline, albuterol, salbutamol, formoterol, salmeterol, indacaterol, terbutaline, orciprenaline, bitolterol mesylate and pirbuterol or methylxanthines such as theophylline, oxitriphylline and aminophylline, mast cell stabilisers such as sodium cromoglycate or muscarinic receptor antagonists such as tiotropium, aclidinium and ipratropium; antihistamines, for example histamine H.sub.1 receptor antagonists such as loratadine, cetirizine, desloratadine, levocetirizine, fexofenadine, astemizole, azelastine, olopatadine and chlorpheniramine or H.sub.4 receptor antagonists; .alpha..sub.1 and .alpha..sub.2 adrenoreceptor agonists such as propylhexedrine phenylephrine, phenylpropanolamine, pseudoephedrine, naphazoline hydrochloride, oxymetazoline hydrochloride, tetrahydrozoline hydrochloride, xylometazoline hydrochloride and ethylnorepinephrine hydrochloride; modulators of chemokine receptor function, for example CCR1, CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10 and CCR11 (for the C-C family) or CXCR1, CXCR2, CXCR3, CXCR4 and CXCR5 (for the C-X-C family) and CX.sub.3CR1 for the C-X.sub.3-C family; Leukotriene antagonists such as montelukast, pranlukast and zafirlukast leukotriene biosynthesis inhibitors such as 5-lipoxygenase inhibitors or 5-lipoxygenase activating protein (FLAP) inhibitors such as zileuton, atreleuton, fenleuton, tepoxalin, 1-[4-[5-(4-fluorophenoxy)furan-2-yl]but-3-yn-2-yl]-1-hydroxyurea, N-(5-substituted)-thiophene-2-alkylsolfonamides, 2,6-di-tert-butylphenol hydrazones, methoxytetrahydropyrans such as 6-[[3-fluoro-5-(4-methoxyoxan-4-yl)phenoxy]methyl]-1-methylquinolin-2-one- , 1-[(3S)-6-[(2,6-difluorophenyl)methoxy]-2,3-dihydro-1-benzofuran-3-yl]-1- -hydroxyurea, pyridinyl-substituted-2-cyanonaphthalene compounds such as [1S,5R]-3-cyano-1-(3-furyl 6-{6-[3-(3.alpha.-hydroxy-6,8-dioxabicyclo[3.2.1]octanyl)]pyridin-2-yl-me- thoxy}naphthalene, 2-cyanoquinoline compounds such as [1S,5R]-2-cyano-4-(3-furyl)-7-3-fluoro-5-[3-(3.alpha.-hydroxy-6,8-dioxabi- cyclo[3.2.1]-octanyl)]phenoxymethyl quinoline, indole and quinoline compounds such as quiflapon, 1-[(4-chlorophenyl)methyl]-3-[(1,1-dimethylethyl)thio]-.alpha.,.alpha.-di- methyl-5-(1-methylethyl)-1H-indole-2-propanoic acid and (2R)-2-cyclopentyl-2-[(4-quinolin-2-ylmethoxy)phenyl]acetic acid; Phosphodiesterase inhibitors, including PDE4 inhibitors such as roflumilast; anti-IgE antibody therapies such as omalizumab; anti-infectives such as fusidic acid (particularly for the treatment of atopic dermatitis); anti-fungals such as clotrimazole (particularly for the treatment of atopic dermatitis); immunosuppressants such as tacrolimus and particularly pimecrolimus in the case of inflammatory skin disease or alternatively rapamycin, cyclosporine, azathioprine or methotrexate; Immunotherapy agents including allergen immunotherapy such as Grazax; corticosteroids such as prednisone, prednisolone, flunisolide, ciclesonide, triamcinolone acetonide, beclomethasone dipropionate, budesonide, fluticasone propionate mometasone furoate and fluticasone furoate; drugs which promote Th1 cytokine response such as interferons, TNF or GM-CSF; and therapies that are in development for inflammatory indications including: other antagonists of PGD.sub.2 acting at other receptors such as DP antagonists; drugs that modulate cytokine production such as inhibitors of TNF.alpha. converting enzyme (TACE) anti-TNF monoclonal antibodies, TNF receptor immunoglobulin molecules, inhibitors of other TNF isoforms, non-selective COX-1/COX-2 inhibitors such as piroxicam, diclofenac, propionic acids such as naproxen, flubiprofen, fenoprofen, ketoprofen and ibuprofen, fenamates such as mefanamic acid, indomethacin, sulindac and apazone, pyrazolones such as phenylbutazone, salicylates such as aspirin; COX-2 inhibitors such as meloxicam, celecoxib, rofecoxib, valdecoxib and etoricoxib, low dose methotrexate, lefunomide, ciclesonide, hydroxychloroquine, d-penicillamine, auranofin or parenteral or oral gold; drugs that modulate the activity of Th2 cytokines including IL-4, IL-5, IL-9, IL-13 and their receptors, for example blocking monoclonal antibodies (e.g. mepolizumab) and soluble receptors; PPAR-.gamma. agonists such as rosiglitazone, piaglitazone; or with anti-RSV antibodies such as Synagis (palivizumab) and agents that may be used to treat rhinovirus infection in the future e.g. interferon-alpha, interferon-beta or other interferons.

25. The composition as claimed in claim 24, wherein the additional active agent is selected from the group consisting of montelukast, pranlukast, zafirlukast, loratadine, cetirizine, desloratadine, levocetirizine, fexofenadine, astemizole, azelastine, olopatadine, and chlorpheniramine.

26. The composition as claimed in claim 24, wherein the stable composition and one or more additional active agents are combined for use in the treatment of a disease or condition mediated by the action of PGD.sub.2 at the CRTH2 receptor.

Summary for Patent:   Start Trial

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom1103837.9Mar 7, 2011

Details for Patent 8,703,956

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Medimmune SYNAGIS palivizumab VIAL 103770 001 1998-06-19   Start Trial Atopix Therapeutics Limited (Abingdon, Oxon, GB) 2031-03-07 RX search
Medimmune SYNAGIS palivizumab VIAL 103770 002 1998-06-19   Start Trial Atopix Therapeutics Limited (Abingdon, Oxon, GB) 2031-03-07 RX search
Genentech XOLAIR omalizumab VIAL 103976 001 2003-06-20   Start Trial Atopix Therapeutics Limited (Abingdon, Oxon, GB) 2031-03-07 RX search
Glaxosmithkline Llc NUCALA mepolizumab INJECTABLE;SUBCUTANEOUS LYOPHILIZED POWER 125526 001 2015-11-04   Start Trial Atopix Therapeutics Limited (Abingdon, Oxon, GB) 2031-03-07 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Baxter
McKinsey
Medtronic
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.